

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/054646 A1

(51) International Patent Classification⁷: **A61M 15/00**

(21) International Application Number:
PCT/EP2003/014424

(22) International Filing Date:
17 December 2003 (17.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/322,867 18 December 2002 (18.12.2002) US

(71) Applicant (*for all designated States except US*): **QUADRANT TECHNOLOGIES LIMITED** [GB/GB]; 1 Mere Way, Ruddington, Nottinghamshire NG11 6JS (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **YOUNG, Matthew, E.** [GB/GB]; Cokenach Barkway, Herts, Cambridgeshire SG88DL (GB). **KAY, Stuart, Brian, William** [GB/GB]; Cokenach, Barkway, Herts, Cambridgeshire SG88DL (GB). **HARRISON, Neil, R.** [GB/GB]; 17 Fledburgh Drive, Birmingham, West Midlands B761ED (GB).

(74) Agent: **STEVENS, Ian, E.**; Eric, Potter, Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

[Continued on next page]

(54) Title: UNIT DOSE DRY POWDER INHALER



(57) Abstract: A unit dose dry powder inhaler (20) has a dispersion chamber (108), optionally including one or more beads. A blister is supported adjacent to the dispersion chamber (108). A mouthpiece cover (22) is removable from a mouthpiece (96), with movement of the mouthpiece cover (22) causing the blister (120) to open. An air flow path extends past or under the blister (120) and into the dispersion chamber (108). As a result, the blister (120) remains sealed until the inhaler (20) is ready for use. The blister (120) is then automatically opened when the mouthpiece cover (22) is removed from the mouthpiece (96). Pharmaceutical dry powder (126) is released from the blister (120) and entrained in air flow through the inhaler (20), when the user inhales on the mouthpiece (96). The powder (126) is dispersed in air within the dispersion chamber (108).

WO 2004/054646 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

UNIT DOSE DRY POWDER INHALER**FIELD OF THE INVENTION**

[0001] The field of the invention is dry powder inhalers.

BACKGROUND OF THE INVENTION

[0002] Inhalers are used to deliver drugs into a patient's lungs. Typically, an inhaler contains or provides a mixture of drug particles and air or propellant gas. The mixture is delivered via the patient inhaling from a mouthpiece on the inhaler with the air carrying the drug particles into the patient's lungs.

[0003] In dry powder inhalers, the drug particles, in the form of a fine dry powder, are entrained into an airflow, and inhaled by the patient, for treatment for various conditions, for example, bronchial asthma. Drugs delivered via a dry powder inhaler can be used to treat many conditions, including those unrelated to lung conditions, via the systemic absorption of the drug into the bloodstream, via the lung.

[0004] For effective dose delivery using a dry powder inhaler, the powder particles must first be dispersed to form a powder/air aerosol. Various techniques for forming powder aerosols have been proposed. One advantageous technique is described in U.S. Patent No. 6,427, 688 and International Application No. PCT/US01/03248.

[0005] While certain drugs, such as asthma drugs, may be taken several times daily, other drugs, including certain peptides or proteins, are typically taken less frequently. Due to the delay in using these types of drugs after they are removed from their packaging, providing a large number of doses within a single package is not desirable, as some doses may become unusable due to exposure to the environment. In addition, many drugs are susceptible to a short shelf life

when removed from a foil storage pouch or other sealed container, even under nominal environmental conditions. These types of drugs must be used almost immediately after being exposed to the environment. Various other drugs are also most often taken only in a single or a few dose. These may include vaccines, antidotes, pain reducers, anti venoms, as well as many others. Unit dose inhalers are also useful for single dose treatments, non-chronic applications, controlled or very expensive drugs where large quantities of drug would not be acceptable, or for drugs where overdose or abuse would have serious consequences. Unit dose inhalers may also be advantageous for children where providing them with a single dose only avoids the potential for overdosing.

[0006] Inhalation provides several advantages over other delivery techniques such as oral delivery via the mouth or intravenous delivery using a syringe. Inhalation is fast, patient friendly, non-invasive, and can provide rapid absorption into the body. While unit dose inhalers have been proposed in the past, they have met with only varying degrees of success due to performance or other factors. Accordingly, there is a need for an improved unit or single dose inhaler for efficiently providing a prepackaged single dose of a powdered drug.

BRIEF STATEMENT OF THE INVENTION

[0007] In a first aspect, a unit dose dry powder inhaler has a dispersion chamber, optionally including one or more beads. A sealed blister or dose container is supported adjacent to the dispersion chamber. A mouthpiece cover, is removable from a mouthpiece, with movement of the mouthpiece cover causing the blister to tear or shear open. An air flow path extends past, through or under the blister and into the dispersion chamber. The blister remains sealed until the inhaler is ready for use. The blister is then automatically opened when the mouthpiece cover is removed from the

mouthpiece. Pharmaceutical dry powder is released from the blister and entrained in air flow through the inhaler, when the user inhales on the mouthpiece. The powder is dispersed in air within the dispersion chamber and forms an aerosol inhaled by the user.

[0008] In a second aspect, the blister or dose container is formed with a first or top layer and a second or bottom layer. A blister post is attached to at least a portion of the bottom layer. As the mouthpiece cover moves to an open position, the blister post moves away from the blister, shearing out the bottom layer, releasing the dry powder, and forming an air flow path through or by the blister. Hold up of powder within the blister is reduced, thereby more reliably providing a full unit dose to the user.

[0009] In a third and separate aspect, a blister is adhered over an air inlet in a chamber front or top section. A chamber back or bottom section has a top or first plate attached to the chamber front, and a bottom or second piece, including the blister post. In the closed position, a dust cap covers a mouthpiece on the chamber front section. As the dust cap is removed from the mouthpiece, the blister post is moved away from the chamber front section and the blister, tearing or shearing out the bottom layer of the blister, and releasing the powder contents of the blister for inhalation. The dust cap may optionally be omitted, with the mouthpiece covered by a separate rigid or flexible material cover, or by providing the inhaler within a pouch, overwrap or package. In this case, the blister or container is opened via movement of the bottom plate or other surface supporting the blister post.

[0010] Other objects, features, and advantages will appear from the following detailed description.

[0011] The invention resides as well in subcombinations of the features and steps shown and described.

[0012] It is an object of the invention to provide an improved unit dose dry powder inhaler.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In the drawings, wherein the same reference number indicates the same element, in each of the views:

[0014] Fig. 1 is a top perspective view of the present unit dose dry powder inhaler, in the closed or storage position.

[0015] Fig. 2 is a bottom perspective view of the inhaler shown in Fig. 1.

[0016] Fig. 3 is a top perspective view of the dust cap or mouthpiece cover shown in Fig. 1, before assembly.

[0017] Fig. 4 is a bottom or rear perspective view of the chamber back section shown in Figs. 1 and 2, with the back chamber assembly shown in an unfolded or unassembled condition, for purpose of illustration.

[0018] Fig. 5 is a top or front view of the chamber back section shown in Fig. 4.

[0019] Fig. 6 is a top perspective view showing the first and second plates forming the chamber back section being moved together for manufacture of the inhaler.

[0020] Fig. 7 is a top perspective view showing the chamber back section of Figs. 4-6 in a fully pre-assembled component.

[0021] Fig. 8 is a top perspective view of the chamber front section.

[0022] Fig. 9 is a bottom or rear perspective view of the chamber front section shown in Fig. 8.

[0023] Fig. 10 is a top perspective view of the chamber back section shown in Figs. 4-7 joined to or assembled with the chamber front section shown in Figs. 8 and 9, to form a chamber assembly.

[0024] Fig. 11 is a top perspective view similar to Fig. 10, and showing adhesive applied to illustrate the manufacturing process.

[0025] Fig. 12 is a top perspective view showing a blister adhered to the assembly of Fig. 11.

[0026] Fig. 13 is a top perspective view of the fully assembled unit dose dry powder inhaler, in the open position, with the dust cap of Fig. 3 attached to the dispersion chamber assembly shown in Fig. 12.

[0027] Fig. 14 is a bottom and side perspective view of the inhaler shown in Fig. 13.

[0028] Fig. 15 is a section view taken along line 15-15 of Fig. 1, and showing the inhaler in the closed position.

[0029] Fig. 16 is a section view similar to Fig. 15, and showing the inhaler in the open position.

[0030] Fig. 17 is an enlarged detail view of the blister and inhaler components shown in Fig. 16.

DETAILED DESCRIPTION OF THE DRAWINGS

[0031] Turning now to the drawings, as shown in Figs. 1, 2, 13 and 14, a unit dose inhaler 20 includes a back section 60 attached to a front section 90 which is covered by a dust cap 22. Figs. 1 and 2 show the inhaler 20 in the closed or storage position. The inhaler 20 as shown in Fig. 2 may optionally be enclosed within a sealed pouch, overwrapper or container 26. Hence, while preferred, the dust cap 22 itself is not essential.

[0032] Fig. 3 shows the dust cap 22 as a separate component, before assembly into the inhaler of Figs. 1 and 2. As shown in Fig. 3, the dust cap 22 includes a generally cylindrical cap section 32 formed in a base plate 34. A shield plate 44 is connected to the base plate 34 by a flex joint or hinge 40. An actuating tab or tooth 50 extends into a hinge slot 42 in the shield plate 44 at the flex or hinge

joint 40. A blister shield dome 46 is formed in the shield plate 44 between the hinge slot 42 and an edge cut-out 48. The shield dome 46 protrudes upwardly in the opposite direction of cap section 32, as shown in Fig. 3, which shows the bottom surface of the dust cap 22 in its unassembled position. A clearance hole 38 is located in the base plate 34, so that when the shield plate 44 is folded over against the base plate 34, as shown in Fig. 1, the blister shield dome 46 is aligned within and protrudes through the clearance hole 38. A lift tab 36 on the base plate 34 provides a finger grasping surface, for actuating the inhaler from the position shown in Fig. 1, to the position shown in Fig. 14.

[0033] The dust cap 22, as well as the front section 90 and back section 60, are preferably made from molded plastics materials, with all features molded in.

[0034] Turning now to Figs. 4, 5, 6, and 7, the back section 60 includes a shear plate 62 attached to a chamber plate 64 by a flex joint or hinge 66. As shown in Figs. 4 and 5, a plate tab 68 and blister post 70 extend downwardly from the shear plate 62. A chamber clearance hole 72 is provided in the shear plate 62 adjacent to the hinge 66. The chamber plate 64 has a notch 80 to provide clearance for the plate tab 68. Similarly, a blister post clearance hole 78 is provided in the chamber plate 64 to provide clearance for the blister post 70, when the shear plate 62 and chamber plate 64 are folded together to form the back section 60.

[0035] Referring still to Figs. 4 and 5, a rear chamber wall 74 is formed in the chamber plate 64 adjacent to the hinge 66. A rear air inlet slot or passageway 76 in the chamber plate 64 extends from the tab slot 80, over the blister post clearance hole 78 and into the chamber rear wall 74, as best shown in Fig. 5. The back section 60 is assembled by folding the shear plate 62 and chamber plate 64 together, as shown in Figs. 6 and 7. The plate tab 68 moves into the tab slot 80. The blister post 70 extends up through the

blister post clearance hole 78. The chamber clearance hole 72 provides clearance for the rearward or downwardly projecting chamber rear wall 74.

[0036] As shown in Fig. 7, as preassembled, the shear plate 62 is substantially flush against the chamber plate 64. The plate tab 68 and slot 80 are dimensioned to provide a snap fit.

[0037] Turning to Figs. 8 and 9, the front section 90 has a generally cylindrical mouthpiece 96 and chamber tube 98 extending upwardly and perpendicularly from a blister plate 92. A blister opening 94 is provided in the blister plate 92, to provide clearance for a blister. A blister plate tab slot 102 is provided at the top end of the blister plate 92, and is adapted to provide clearance for, and a snap fit with, the plate tap 68. A shield plate step 100 extends across the blister plate 92, to facilitate assembly of the components of the inhaler 20.

[0038] Referring to Fig. 9, a curved or domed front chamber wall 106 is formed in the blister plate 92, concentric with the chamber tube 98. A front air inlet 104 extends from the blister plate tab slot 102 over the blister opening 94 and into the front chamber wall 106, similar to the complimentary features 76, 78, and 74 in the back section 60.

[0039] Referring to Fig. 10, the assembled back section 60, as shown in Fig. 7, is attached to the front section 90, via adhesives, sonic welding, snap fit, etc. As shown in Fig. 10, the back section 60 assembled with the front section 90, together form a dispersion or chamber assembly 88. The top surface of the chamber plate 64 is attached to the bottom surface of the blister plate 92. The chamber back wall 74 in the chamber plate 64 aligns and comes together with the chamber front wall 106 of the front section 90. The rear air inlet 80 on the chamber plate 64 aligns and comes together with the front air inlet 104 in the blister

plate 92, connecting into the dispersion chamber 108 formed by the back and front chamber walls 74 and 106. The blister post 70 extends up through the blister opening 94 in the blister plate 92. The top surface of the blister post 70 is substantially level with the top surface of the blister plate 92. The annular clearance or spacing between the blister post 70 and the blister plate 92 surrounding it ranges from 1-10, 2-6, or 3-5 mm. This spacing allows the blister post to tear or shear out the bottom of the blister, without causing the blister to crush in or extensively deform.

[0040] As shown in Figs. 11 and 12, an adhesive is applied to the blister plate 92 around the blister opening 94. The adhesive 110 is also applied to the top surface of the blister post 70. A blister 120 is then adhered to the top surface of the blister plate 92, with the dome or hemispherical section of the blister extending upwardly (in the same direction as the mouthpiece 96). The blister 120 contains a dry pharmaceutical powder 126 sealed between a base layer 122 and a shear layer 124. These layers are typically metal foil and may include other layers as well. Various blisters may be used as described, for example, in U.S. Patent No. 4,778,054, or International Patent Publication WO 01/72605.

[0041] Referring to Fig. 13, the dustcap 22 is then assembled to the chamber assembly 88. Specifically, the shield plate 44 is placed over the blister 120, with the outer edges of the shield plate 44 in contact with the adhesive 110. This step is performed with the shield plate 44 folded over at the flex joint 40, so that the shield plate 44 is in contact with the base plate 34. With the completion of this step, the inhaler 20 is fully assembled, as shown in Figs. 1 and 2. The inhaler 20 may then be placed into a sealed envelope or overwrap 26.

[0042] The dispersion chamber 108 formed by bringing together the chamber back wall 74 of the back section 60 and

the chamber front wall 106 of the front section 90 has an inner rim 114 at the bottom end of the chamber tube 98 as shown in Fig. 15. One or more beads 112 are captive within the dispersion chamber 108, as described in International Patent Publication WO 01/56640. The rear air inlet 76 and the front air inlet 104 together form a chamber inlet 116, extending from the top end of the inhaler 20 (at the slots 80 and 102), extending over (and/or around) the blister post 70 and into the dispersion chamber 108. One or more sheath air openings 115 may optionally be provided through the mouthpiece 96.

[0043] In use, as shown in Figs. 1, 2, and 15, the dust cap 22 is in place over the mouthpiece 96. The pharmaceutical dry powder 126 is sealed within the blister 120. The blister 120 is enclosed on top by the shield dome 46 and by the shear plate 62 below, to better avoid physical damage to the blister 120 during storage and handling. The beads 112 are placed within the dispersion chamber 108 before the back section 60 and front section 90 are joined together. The inner rim 114 prevents the beads 112 from moving out of the dispersion chamber 108 through the chamber tube 98.

[0044] The user lifts up on the lift tab 36, pivoting the base plate 34 from the closed position shown in Fig. 15, to the open position shown in Fig. 16. This removes the cap section 32, if used, from the mouthpiece 96.

[0045] Referring to Figs. 15, 16, and 17, as the base plate 34 is pivoted to the open position, the tab tooth 50 pushes down on the plate tab 68, with a cam-like movement. This drives the shear plate 62 downwardly. The blister post 70 moves down with the shear plate 62. As the shear layer 124 or bottom layer of the blister 120 is adhered to the blister post 70, the movement of the blister post 70 shears or tears out the shear layer 124 of the blister 120. As this occurs, some of the powder 126 in the blister 120 will move or fall out of the blister 120 into the air inlet or flow path 116.

Some of the powder 126 remains on top of the now separated shear layer 124' shown in Fig. 17.

[0046] The user then places the mouthpiece 96 in the mouth and inhales. Air is drawn through the inlet 116 carrying the powder 126 into the chamber 108. The air inlet 116 extends into the chamber 108 on a chord or tangentially. The air drawn through the chamber 108 causes the beads 112 to circulate rapidly around in the chamber. This bead movement disperses and mixes the powder 126 with air. The air and powder then move out of the chamber 108 through the chamber tube 98, for inhalation by the user. Sheath or bleed air, if used, flows in through the openings 115 and moves generally parallel to the cylindrical side-walls of the mouthpiece 96. The sheath air helps to reduce deposition of powder particles in the mouth and throat allowing more of the particles to reach the lung.

[0047] While the inhaler 20 may be used in any orientation, the top end, at the plate tab 68, is preferably to the side, or above the mouthpiece 96, for better movement of powder 126 into the chamber 108. After use, the inhaler 20 may be collected for recycling, or it may be discarded.

CLAIMS

1. An inhaler comprising:
a dispersion chamber;
a dose container containing a pharmaceutical between a first layer and a second layer; and
a surface of the inhaler adhered to at least a portion of the second layer, and with that surface moveable relative to the dispersion chamber, for opening the container.
2. The inhaler of claim 1 further wherein the dose container comprises a blister and the surface of the inhaler adhered to the blister includes a blister post, and further including a mouthpiece associated with the dispersion chamber and with the blister post on a shear plate, and including a mouthpiece cover pivotable relative to the shear plate for moving the blister post away from the blister to open the blister.
3. The inhaler of claim 2 with the mouthpiece cover having a cap section adapted to fit over the mouthpiece, a base plate, and a shield plate including a blister shield dome covering the first layer of the blister.
4. The inhaler of claim 2 with the mouthpiece including a chamber tube connecting into the dispersion chamber within a mouthpiece cylinder attached onto a blister plate.
5. The inhaler of claim 4 wherein an outer perimeter area of the second layer of the blister is attached to the blister plate.
6. The inhaler of claim 2 further including a chamber plate overlying the shear plate, and with the chamber plate including a blister post clearance hole around the blister

post, a dispersion chamber back wall, and a back air inlet slot.

7. The inhaler of claim 6 with the mouthpiece including a dispersion chamber front wall, and with the dispersion chamber formed by the dispersion chamber back wall of the chamber plate joined with the dispersion chamber front wall of the mouthpiece.

8. The inhaler of claim 7 with the mouthpiece including a front air inlet slot, with the back air inlet slot of the chamber plate and the front air inlet slot of the mouthpiece forming an air inlet passing around the blister post and connecting into the dispersion chamber.

9. The inhaler of claim 6 with the shear plate attached to the chamber plate and further including plate tab engageable by the mouthpiece cover.

10. The inhaler of claim 9 further including a tab tooth on the mouthpiece cover engageable against the plate tab, as the mouthpiece cover is moved away from the mouthpiece, to drive blister post on the shear plate away from the blister plate to open the blister.

11. The inhaler of claim 10 with a first end of the shear plate attached to a first end of the chamber plate, and with the plate tab on a second end of the chamber plate opposite the first end thereof, with the second end of the chamber plate moveably away from the chamber plate and the blister, upon engagement of the plate tab by the tab tooth of the mouthpiece cover.

12. A dry powder inhaler comprising:

a first plate having an air passageway leading into a chamber;

a mouthpiece connecting with the chamber;

a dose container on the first plate;

a second plate having a surface or element attached to at least part of the dose container; and

a pivot connection for moving an end of the second plate away from the first plate, to cause the dose container to open.

13. A dry powder inhaler comprising:

a mouthpiece;

a blister supported on the mouthpiece;

a mouthpiece cover;

means for opening the blister by removing the mouthpiece cover from the mouthpiece.

14. A method for delivering a unit dose of a dry powder pharmaceutical, comprising the steps of:

pivoting a mouthpiece cover away from a mouthpiece of an inhaler;

moving a blister post adhered to a portion of the blister away from the blister with the pivoting movement of the mouthpiece;

shearing open the blister via the blister post;

allowing at least some of a dry powder pharmaceutical in the blister to deposit into an air passageway leading into a dispersion chamber;

drawing air through the dispersion chamber and air passageway and out through the mouthpiece.




FIG. 1





FIG. 2

**FIG. 3**




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13





FIG. 14

**FIG. 15**




FIG. 16




FIG. 17

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/14424

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BE 863 721 A (ALLEN & HANBURY LTD) 7 August 1978 (1978-08-07) page 6, line 4 - page 8, line 14; figures 1-5	1
X	US 6 029 663 A (CAMERON ALLAN ET AL) 29 February 2000 (2000-02-29)	1,12
Y	column 3, line 9 - line 52; figures 5-9	2-5
X	US 2002/040713 A1 (HOLTON NELSON ET AL) 11 April 2002 (2002-04-11)	13
Y	paragraph '0042! - paragraph '0048!; figures	2-5
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

23 April 2004

Date of mailing of the international search report

03/05/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Zeinstra, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/14424

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/26720 A (BRUNNBERG LENNART ; OLSSON THOMAS (SE); SHL MEDICAL AB (SE)) 19 April 2001 (2001-04-19) page 12, line 16 - page 13, line 30; figures 1-6 -----	13
A	US 4 778 054 A (NEWELL ROBERT E ET AL) 18 October 1988 (1988-10-18) cited in the application column 4, line 8 - column 5, line 4; figures 3,4 -----	1,12,13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/14424

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **14**
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 14

Rule 39.1(iv) PCT – Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/14424

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
BE 863721	A	07-08-1978	AU 510344 B2	19-06-1980
			AU 3305178 A	16-08-1979
			BE 863721 A1	07-08-1978
			CA 1115613 A1	05-01-1982
			CH 625127 A5	15-09-1981
			DE 2804852 A1	17-08-1978
			ES 466842 A1	16-08-1979
			FI 780365 A ,B,	11-08-1978
			FR 2380032 A1	08-09-1978
			GB 1598081 A	16-09-1981
			IE 46205 B1	23-03-1983
			IT 1102046 B	07-10-1985
			JP 1618608 C	30-09-1991
			JP 2024547 B	29-05-1990
			JP 53100695 A	02-09-1978
			NL 7801331 A	14-08-1978
			SE 7801431 A	11-08-1978
			US 4210140 A	01-07-1980
			ZA 7800544 A	25-07-1979
US 6029663	A	29-02-2000	US 5622166 A	22-04-1997
			US 6328034 B1	11-12-2001
			AT 258450 T	15-02-2004
			AU 695051 B2	06-08-1998
			AU 5251096 A	18-11-1996
			BG 62921 B1	30-11-2000
			BG 101992 A	31-07-1998
			BR 9608194 A	21-07-1998
			CA 2217672 A1	31-10-1996
			CN 1181709 A	13-05-1998
			CZ 9703349 A3	14-01-1998
			DE 69631419 D1	04-03-2004
			EP 0835147 A1	15-04-1998
			HU 9801656 A2	28-10-1998
			IL 117706 A	30-11-1999
			JP 10512788 T	08-12-1998
			NO 974910 A	24-10-1997
			NZ 304654 A	28-01-1999
			PL 322909 A1	02-03-1998
			RO 115407 B1	28-02-2000
			RU 2162717 C2	10-02-2001
			SK 144697 A3	04-03-1998
			TW 384225 B	11-03-2000
			US 2002040713 A1	11-04-2002
			WO 9633759 A1	31-10-1996
			US 5921237 A	13-07-1999
			AU 729272 B2	01-02-2001
			AU 3646697 A	10-02-1998
			BR 9710880 A	17-08-1999
			CZ 9900189 A3	12-05-1999
			EP 0925084 A1	30-06-1999
			HU 9903819 A2	28-03-2000
			JP 2001507949 T	19-06-2001
			NO 990272 A	22-03-1999
			NZ 333685 A	29-09-2000
			NZ 505722 A	30-03-2001
			WO 9803217 A1	29-01-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/14424

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002040713 A1	11-04-2002	US 6328034 B1	11-12-2001
		US 5622166 A	22-04-1997
		US 5921237 A	13-07-1999
		AU 729272 B2	01-02-2001
		AU 3646697 A	10-02-1998
		AU 695051 B2	06-08-1998
		AU 5251096 A	18-11-1996
		BG 62921 B1	30-11-2000
		BG 101992 A	31-07-1998
		BR 9608194 A	21-07-1998
		BR 9710880 A	17-08-1999
		CA 2217672 A1	31-10-1996
		CN 1181709 A	13-05-1998
		CZ 9900189 A3	12-05-1999
		CZ 9703349 A3	14-01-1998
		EP 0835147 A1	15-04-1998
		EP 0925084 A1	30-06-1999
		HU 9801656 A2	28-10-1998
		HU 9903819 A2	28-03-2000
		IL 117706 A	30-11-1999
		JP 2001507949 T	19-06-2001
		JP 10512788 T	08-12-1998
		NO 974910 A	24-10-1997
		NO 990272 A	22-03-1999
		NZ 304654 A	28-01-1999
		NZ 333685 A	29-09-2000
		NZ 505722 A	30-03-2001
		PL 322909 A1	02-03-1998
		RO 115407 B1	28-02-2000
		RU 2162717 C2	10-02-2001
		SK 144697 A3	04-03-1998
		TW 384225 B	11-03-2000
		WO 9633759 A1	31-10-1996
		WO 9803217 A1	29-01-1998
		US 6029663 A	29-02-2000
		AT 258450 T	15-02-2004
		DE 69631419 D1	04-03-2004
		CA 2261172 A1	29-01-1998
WO 0126720 A	19-04-2001	SE 521913 C2	16-12-2003
		SE 518512 C2	15-10-2002
		AU 1068401 A	23-04-2001
		EP 1220698 A1	10-07-2002
		WO 0126720 A1	19-04-2001
		SE 9903677 A	13-04-2001
		SE 0000092 A	14-07-2001
US 4778054 A	18-10-1988	AT 396333 B	25-08-1993
		AT 357683 A	15-12-1992
		AU 570013 B2	03-03-1988
		AU 1997783 A	12-04-1984
		AU 584535 B2	25-05-1989
		AU 8315587 A	21-04-1988
		BE 897946 A1	09-04-1984
		BR 8305562 A	15-05-1984
		CA 1224992 A1	04-08-1987
		CA 1236736 A2	17-05-1988
		CH 662277 A5	30-09-1987

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/14424

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4778054	A	CY 1477 A	21-07-1989
		CY 1478 A	21-07-1989
		DE 3336486 A1	26-04-1984
		DE 3348370 C2	11-10-2001
		DK 45198 A	20-12-1999
		DK 464383 A	09-04-1984
		ES 286422 U	01-02-1986
		FI 833641 A ,B,	09-04-1984
		FI 891175 A ,B,	13-03-1989
		FR 2550452 A1	15-02-1985
		FR 2570607 A1	28-03-1986
		GB 2129691 A ,B	23-05-1984
		GB 2169265 A ,B	09-07-1986
		GR 79615 A1	31-10-1984
		HK 67689 A	01-09-1989
		HK 67789 A	01-09-1989
		IE 56059 B1	10-04-1991
		IE 56060 B1	10-04-1991
		IL 69932 A	31-12-1987
		IL 80468 A	30-11-1987
		IN 160851 A1	08-08-1987
		IT 1203660 B	15-02-1989
		JP 4131250 U	02-12-1992
		JP 59088158 A	22-05-1984
		JP 1888266 C	07-12-1994
		JP 5076872 B	25-10-1993
		JP 5200100 A	10-08-1993
		KE 3860 A	02-06-1989
		KE 3861 A	02-06-1989
		KR 9102248 B1	08-04-1991
		LU 85034 A1	19-06-1985
		NL 8303461 A ,B,	01-05-1984
		NL 9700002 A ,B,	02-06-1997
		NO 833667 A ,B,	09-04-1984
		NZ 205892 A	31-07-1987
		NZ 218860 A	26-04-1989
		PT 77471 A ,B	01-11-1983
		SE 458824 B	16-05-1989
		SE 8305542 A	09-04-1984